Although lower levels of S2-reactive CD8+TSCM was observed in participants with type 2 diabetes following their second dose (Supplementary Figure 10B), this reduction did not affect the proportion of S2-reactive CD8+T cells at 3-6 months after vaccination (Supplementary Figures S5C, 6C). Here, CD8A is linked to type 2 diabetes mellitus.